New
Tesamorelin
199,95 €
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- FDA Approves Treatment to Reduce Visceral Fat Associated with HIV.
- Significant reduction in visceral fat in clinical trials.
- Improvement in lipid profile and metabolic health.
- Preservation of GH’s natural pulsatile physiology.
- Cognitive Benefits: IGF-1 Modulation in Research on Mild Cognitive Impairment.
Description
Tesamorelin
Growth hormone / Visceral fat
MECHANISM OF ACTION
A stabilized synthetic analog of GHRH, with a trans-3-hexenoic acid modification that improves metabolic stability. It binds to the GHRH receptor in the anterior pituitary with high affinity, stimulating the pulsatile release of GH. Its pulsatile profile preserves natural feedback. The subsequent increase in IGF-1 mediates the reduction of visceral fat through enhanced lipolysis.
KEY BENEFITS
- FDA Approves Treatment to Reduce Visceral Fat Associated with HIV.
- Significant reduction in visceral fat in clinical trials.
- Improvement in lipid profile and metabolic health.
- Preservation of GH’s natural pulsatile physiology.
- Cognitive Benefits: IGF-1 Modulation in Research on Mild Cognitive Impairment.
SIDE EFFECTS AND SAFETY
The most common side effects are injection-site reactions, fluid retention, joint pain, and glucose intolerance. Monitor HbA1c. Monitoring of IGF-1 is recommended.
RESEARCH AND CLINICAL NOTES
AWARE Trial: Tesamorelin reduced visceral adipose tissue by 15–20% at 26 weeks compared with placebo in HIV-associated lipodystrophy. Approved by the FDA as Egrifta. Off-label use for visceral obesity not associated with HIV is expanding.
TARGET PROFILE:
HIV medicine, metabolic medicine, visceral fat management programs, and anti-aging protocols.
Additional information
| Weight | ,26 kg |
|---|
You may also like…
Hot
Algal Oil Omega 3 EPA/DHA, 100 capsules
- Vegan source of Omega-3: Schizochytrium microalgae oil, a sustainable alternative to fish oil.
- Cardiovascular health: DHA and EPA help reduce triglycerides, improve circulation, and control blood pressure.
- Brain and cognitive wellness: Supports memory, concentration, and prevents cognitive decline.
- Eye health: DHA is an essential component of the retina, helping maintain optimal vision.
- Anti-inflammatory properties: Alleviates symptoms of arthritis and other chronic inflammatory diseases.
- Suitable for vegans: Free from gluten, lactose, and preservatives.
Related products
5-Amino-1MQ
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Accelerated lipolysis and fat oxidation without thermogenic effects.
- Improved mitochondrial efficiency and ATP production.
- Supports insulin sensitivity and glucose homeostasis.
- Interest in body recomposition protocols in combination with GLP-1 agonists.
- Supports NAD+ levels relevant to cellular longevity.
New
AOD-9604
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Targeted fat loss without IGF-1-mediated growth effects.
- No effect on blood glucose or insulin sensitivity.
- Fat reduction is well tolerated in patients with metabolic disorders and diabetes.
- It supports body recomposition when combined with exercise.
- Being investigated for cartilage repair (TGA approval in Australia for OA).
New
BPC 5 mg + TB 5 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Faster soft tissue repair than with any of the peptides alone.
- Coverage for localized repair (BPC-157) and systemic repair (TB-500).
- Reduction of inflammation and pain following an injury.
- Recovery of joints, tendons, ligaments, and muscles.
- A convenient, single-vial protocol for injury recovery.
IGF-1 LR3
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Powerful anabolic effect: muscle hypertrophy and hyperplasia.
- Improved protein synthesis and nitrogen retention.
- Improved glucose utilization and fat oxidation.
- Accelerated injury healing and tissue regeneration.
- Extended half-life that allows for once-daily dosing.
New
Retatrutide 10 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Body weight reduction of up to 24% in Phase II trials; the most potent in its class.
- Greater reduction in body fat compared to tirzepatide.
- Improved glycemic control through multiple mechanisms.
- Improvement in cardiovascular risk factors.
- Potential for treating NASH and reducing liver fat.
New
Retatrutide 20 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Body weight reduction of up to 24% in Phase II trials; the most potent in its class.
- Greater reduction in body fat compared to tirzepatide.
- Improved glycemic control through multiple mechanisms.
- Improvement in cardiovascular risk factors.
- Potential for treating NASH and reducing liver fat.
New
Selank
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Rapid anxiolytic effect without sedation or dependence.
- Cognitive improvement: memory consolidation and processing speed.
- Mood stabilization and resilience to stress.
- Modulation of the immune system through tuftsin activity.
- Minimal side effects compared to benzodiazepines.
- Used clinically in Russia to treat anxiety and cognitive disorders.
Snap-8
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Non-invasive wrinkle reduction equivalent to botulinum toxin, though gentler and safer.
- Reduction in the depth of dynamic wrinkles on the forehead, crow's feet, and glabellar lines.
- Used in conjunction with Matrixyl and GHK-Cu in comprehensive anti-aging regimens.
- Active ingredient for cosmetic formulations or injectable administration.
- The preferred alternative for patients seeking options that do not involve botulinum toxin.
